Valutazione economica di ticagrelor vs Clopidogrel nel trattamento di pazienti con sindrome coronarica acuta

Ticagrelor is a new generation drug for the prevention of thrombotic events in patients with acute coronary syndrome (ACS). This study is a cost-effectiveness analysis of ticagrelor vs clopidogrel (the current standard) in the economic perspective of the National Health Service (NHS) in Italy. It is based on the clinical outcomes of an international, randomized, double-blind trial (PLATO study).